Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Biperiden · Akineton

Small molecule · developed by Abbvie

Approved FDA, Sep 1959
1 Registered trials

What is Biperiden?

Biperiden is a small-molecule anticholinergic agent. It is used as an adjunct in parkinsonism and in extrapyramidal disorders caused by neuroleptic drugs, and is also studied in traumatic brain injury and post-traumatic epilepsy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Akineton
Drug type
Small molecule
Therapy area
Neurology
Developer
Abbvie
In trials of
RFL
FDA status
Approved as Akineton (September 8, 1959), NDA012003 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 16, 2012). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04945213 Phase 3 Brain Injury Traumatic Moderate Recruiting RFL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Brain Injury Traumatic ModerateBrain Injury Traumatic SeverePost Traumatic Epilepsy

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.